Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.66
BEAT's Cash to Debt is ranked higher than
81% of the 302 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. BEAT: 0.66 )
BEAT' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 0.66

Equity to Asset 0.54
BEAT's Equity to Asset is ranked higher than
81% of the 303 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. BEAT: 0.54 )
BEAT' s 10-Year Equity to Asset Range
Min: -1.16   Max: 0.92
Current: 0.54

-1.16
0.92
F-Score: 4
Z-Score: 1.65
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2.17
BEAT's Operating margin (%) is ranked higher than
56% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 8.59 vs. BEAT: -2.17 )
BEAT' s 10-Year Operating margin (%) Range
Min: -160.62   Max: 8.05
Current: -2.17

-160.62
8.05
Net-margin (%) -5.20
BEAT's Net-margin (%) is ranked higher than
56% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 4.91 vs. BEAT: -5.20 )
BEAT' s 10-Year Net-margin (%) Range
Min: -160.04   Max: 7.64
Current: -5.2

-160.04
7.64
ROE (%) -12.53
BEAT's ROE (%) is ranked higher than
53% of the 286 Companies
in the Global Medical Care industry.

( Industry Median: 9.56 vs. BEAT: -12.53 )
BEAT' s 10-Year ROE (%) Range
Min: -799.96   Max: 14.94
Current: -12.53

-799.96
14.94
ROA (%) -7.80
BEAT's ROA (%) is ranked higher than
53% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 3.52 vs. BEAT: -7.80 )
BEAT' s 10-Year ROA (%) Range
Min: -100.54   Max: 6.85
Current: -7.8

-100.54
6.85
ROC (Joel Greenblatt) (%) -13.34
BEAT's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 18.24 vs. BEAT: -13.34 )
BEAT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -195.03   Max: 26.83
Current: -13.34

-195.03
26.83
Revenue Growth (%) 0.70
BEAT's Revenue Growth (%) is ranked higher than
62% of the 239 Companies
in the Global Medical Care industry.

( Industry Median: 6.10 vs. BEAT: 0.70 )
BEAT' s 10-Year Revenue Growth (%) Range
Min: -41   Max: 52.8
Current: 0.7

-41
52.8
EPS Growth (%) -29.30
BEAT's EPS Growth (%) is ranked higher than
58% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 10.90 vs. BEAT: -29.30 )
BEAT' s 10-Year EPS Growth (%) Range
Min: -34.3   Max: -17.1
Current: -29.3

-34.3
-17.1
» BEAT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BEAT Guru Trades in Q4 2013

Jim Simons 664,000 sh (-24.14%)
» More
Q1 2014

BEAT Guru Trades in Q1 2014

George Soros 74,600 sh (New)
Jim Simons 715,800 sh (+7.8%)
» More
Q2 2014

BEAT Guru Trades in Q2 2014

Jim Simons 777,200 sh (+8.58%)
George Soros Sold Out
» More
Q3 2014

BEAT Guru Trades in Q3 2014

Paul Tudor Jones 26,300 sh (New)
Jim Simons 737,300 sh (-5.13%)
» More
» Details

Insider Trades

Latest Guru Trades with BEAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$6.78 - $11.02 $ 9.8724%0
George Soros 2014-03-31 New Buy0.01%$6.88 - $11.71 $ 9.878%74600
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.10
BEAT's P/B is ranked higher than
68% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 2.96 vs. BEAT: 4.10 )
BEAT' s 10-Year P/B Range
Min: 0.42   Max: 5.8
Current: 4.1

0.42
5.8
P/S 1.70
BEAT's P/S is ranked higher than
73% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. BEAT: 1.70 )
BEAT' s 10-Year P/S Range
Min: 0.43   Max: 5.88
Current: 1.7

0.43
5.88
EV-to-EBIT -80.08
BEAT's EV-to-EBIT is ranked lower than
51% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 22.71 vs. BEAT: -80.08 )
BEAT' s 10-Year EV-to-EBIT Range
Min: -77.8   Max: 421.2
Current: -80.08

-77.8
421.2
Current Ratio 1.22
BEAT's Current Ratio is ranked higher than
69% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. BEAT: 1.22 )
BEAT' s 10-Year Current Ratio Range
Min: 0.44   Max: 7.88
Current: 1.22

0.44
7.88
Quick Ratio 1.14
BEAT's Quick Ratio is ranked higher than
70% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 1.21 vs. BEAT: 1.14 )
BEAT' s 10-Year Quick Ratio Range
Min: 0.44   Max: 7.88
Current: 1.14

0.44
7.88

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.50
BEAT's Price/Tangible Book is ranked higher than
72% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 33.51 vs. BEAT: 14.50 )
BEAT' s 10-Year Price/Tangible Book Range
Min: 0.76   Max: 11.67
Current: 14.5

0.76
11.67
Price/DCF (Projected) 6.60
BEAT's Price/DCF (Projected) is ranked higher than
73% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 4.19 vs. BEAT: 6.60 )
BEAT' s 10-Year Price/DCF (Projected) Range
Min: 3.49   Max: 12.69
Current: 6.6

3.49
12.69
Price/Median PS Value 1.50
BEAT's Price/Median PS Value is ranked higher than
70% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. BEAT: 1.50 )
BEAT' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 5.24
Current: 1.5

0.42
5.24
Earnings Yield (Greenblatt) -1.20
BEAT's Earnings Yield (Greenblatt) is ranked higher than
56% of the 302 Companies
in the Global Medical Care industry.

( Industry Median: 4.80 vs. BEAT: -1.20 )
BEAT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.2   Max: 8.5
Current: -1.2

-1.2
8.5

Business Description

Industry: Health Care Providers » Medical Care
Compare: » details
Traded in other countries:C25.Germany
BioTelemetry Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates under three segments; patient services, product and research services. The patient services segment relates to the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Company provides cardiologists and electrophysiologists who prefer to use a single source of cardiac monitoring services with solutions like the differentiated Mobile Cardiac Outpatient TelemetryTM "MCOT" service to wEvent, event, Holter, Pacemaker and International normalized ratio "INR" monitoring. INR monitoring is a measurement of blood coagulation in the circulatory system and is prescribed for patients on long term anticoagulation therapy. The product business segment works on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The research services segment is engaged in central core laboratory services providing cardiac monitoring, scientific consulting and data management services for drug and medical device trials. As of December 31, 2013, the Company had 28 issued U.S. patents and 43 issued foreign patents.
» More Articles for BEAT

Headlines

Articles On GuruFocus.com
CardioNet Inc. Reports Operating Results (10-Q) Nov 09 2010 
CardioNet Inc. Reports Operating Results (10-Q) Aug 02 2010 
CardioNet Inc. Reports Operating Results (10-Q) May 04 2010 
CardioNet Inc. Reports Operating Results (10-Q) Nov 06 2009 
CardioNet Inc. Reports Operating Results (10-Q) Aug 10 2009 
CardioNet, Inc. Reports Second Quarter 2009 Financial Results Aug 05 2009 
CardioNet Inc. (BEAT) CFO Martin P Galvan buys 5,000 Shares May 18 2009 
CardioNet Inc. Reports Operating Results (10-Q) May 15 2009 
CardioNet Inc. (BEAT) CEO Randy H Thurman buys 5,555 Shares May 07 2009 
CardioNet Inc. (BEAT) CFO Martin P Galvan buys 1,000 Shares Mar 02 2009 

More From Other Websites
BioTelemetry (BEAT) Catches Eye: Stock Jumps 5.7% Nov 28 2014
BIOTELEMETRY, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 21 2014
BioTelemetry, Inc. Announces That Eric Prystowsky M.D. Will Transition From the Board of Directors... Nov 19 2014
BioTelemetry, Inc. Announces That Eric Prystowsky M.D. Will Transition From the Board of Directors... Nov 19 2014
Intrexon (XON) Looks Good: Stock Moves 11% Higher Nov 12 2014
Air Methods (AIRM) Crumbles: Stock Falls by 7.9% Nov 10 2014
Biotelemetry (BEAT) Upgraded From Sell to Hold Nov 06 2014
Earnings Estimates Moving Higher for BioTelemetry (BEAT): Time to Buy? Nov 06 2014
Is BioTelemetry (BEAT) Stock a Solid Choice Right Now? Nov 05 2014
Abiomed Tops Q2 Earnings, Revenues; FY15 Sales View Up Nov 04 2014
Strength Seen in Covance (CVD): Stock Surges 25.9% Nov 04 2014
BioTelemetry (BEAT) Shares March Higher, Can It Continue? Nov 04 2014
BIOTELEMETRY, INC. Files SEC form 10-Q, Quarterly Report Oct 31 2014
BioTelemetry Inc Earnings Call scheduled for 5:00 pm ET today Oct 30 2014
BIOTELEMETRY, INC. Files SEC form 8-K, Results of Operations and Financial Condition Oct 30 2014
BioTelemetry, Inc. Reports Third Quarter 2014 Financial Results Oct 30 2014
Q3 2014 BioTelemetry Inc Earnings Release - 4:00 pm ET Oct 30 2014
BioTelemetry, Inc. to Release Third Quarter 2014 Earnings Results on October 30, 2014 Oct 22 2014
BioTelemetry, Inc. to Release Third Quarter 2014 Earnings Results on October 30, 2014 Oct 22 2014
BioTelemetry, Inc. Announces Reinstatement of Cigna Corporation's Coverage of Mobile Cardiac... Oct 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK